two year safety and clinical performance of the drug eluting orsiro stent in the treatment of...
TRANSCRIPT
Two Year Safety And Clinical Performance Of The Drug Eluting Orsiro Stent In The Treatment Of Subjects With Single De Novo Coronary Artery
Lesions(BIOFLOW-II)
Michael Haude, Rafael Ruiz-Salmeron, Thierry Lefévre, Bernhard Witzenbichler, Karl Stangl, Ton Slagboom, Franz-Josef Neumann,
Manel Sabaté, Jean-Cristophe Macia, Gert Richardt, Béla Merkely, Javier Goicolea, Johannes Bilger, Dimitar Divchev, Paul Barragan,
Stéphane Cook, Ron Waksman, Stephan Windecker
Prof. Michael Haude. MD I have the following potential conflicts of interest
to report:
Consultant: BIOTRONIK, ORBUSNEICH Institutional grant/research support: ABBOTT
VASCULAR, BIOTRONIK,MEDTRONIC, ORBUSNEICH,VOLCANO, CARDIAC
DIMENSIONS
Orsiro Hybrid Drug Eluting Stent With Bioabsorbable Polymer
The hybrid structure:
A combination of passive and active components
The underlying PK Energy Stent with thin strut (60μm) design
Passive component encapsulates the stent
Active component contains bioabsorbable PLLA and sirolimus
Overview of Current Stent Designs
Source: Stefanini G., Taniwaki M., Windecker S., Heart 2013; 0:1-11.
DurablePolymer Coated Stent
BioabsorbablePolymer Coated Stent
BIOTRONIK
OrsiroCoCr-SES
60 µm
Circumferential 4-8 µm/side
Boston
SynergyPtCr-EES
74 µm
Abluminal4 µm/side
Terumo
UltimasterCoCr-SES
80 µm
Abluminal15 µm/side
Biosensors
BioMatrix316L-BES
120 µm
Abluminal 10 µm/side
Medtronic
ResoluteCoNi-ZES
91 µm
Circumferential 6 µm/side
Abbott/Boston
Xience/PromusCoCr/PtCr-EES
81 µm
Circumferential 7-8 µm/side
Strut Thickness
PolymerCoating
Company
Device NameMaterial-Drug
DeviceDesign
BIOFLOW II Study Design
Orsiro
452 Patients (Intention To Treat) with de novo lesions in up to two coronary arteriesAll subjects stratified for diabetes
Annual clinical follow-up to 5 years
1,6-month clinical follow-up
Prospective, multicenter, international, randomized, non-inferiority design
Co-PIs: Stephan Windecker, University Hospital Bern, Switzerland Thierry Lefevre, Hospital Jacques Cartier, Massy, France
Xience Prime2:1
9-month clinical and angiographic follow-up IVUS and OCT follow-up in pre-specified subgroups with 60 patients in each
12-month clinical follow-up
ClinicalTrials.gov Identifier: NCT01356888.
Stent Platforms
Co-Cr, L-605
60 µm
Stent material
Strut thickness
Passive coating Silicon carbide
Polymer coating Biodegradable (PLLA)Drug Sirolimus
Orsiro
Co-Cr, L-605
81 µm
-
Durable (PBMA/PVDF-HFP)Everolimus
Xience Prime™
Source: Lefèvre T., Oral presentation, TCT 2013, San Francisco, USA.
Inclusion/Exclusion CriteriaInclusion Criteria
Exclusion Criteria
Co-PIs: Stephan Windecker, University Hospital Bern, Switzerland Thierry Lefevre, Hospital Jacques Cartier, Massy, France
Single de novo lesions in up to 2 native coronary arteries RVD ≥2.25 mm and ≤4.0 mm, lesion lengths ≤26 mm Age ≥18 and ≤80 years old Target vessel(s) TIMI flow ≥ 2 Eligible for DAPT therapy with ASA plus either, Clopidogrel, Prasugrel, Ticlopidine, or
Ticagrelor
Evidence of MI within 72 hours prior to index procedure ≥2xURL CK level or in absence of CK, ≥3xURL CKMB <24 hours prior to PCI Unprotected left main, 3-vessel CAD, thrombotic, ostial or bifurcation (SB>2.0mm), heavily
calcified or lesions in bypass graft LVEF ≤ 30% Serum creatinine > 2.5 mg/dl
ClinicalTrials.gov Identifier: NCT01356888.
OrsiroN= 332
Xience PrimeN= 173
Preprocedure
Lesion Length (mm) 13.4 ± 6.8 13.6 ± 5.6
Reference Vessel Diameter (mm) 2.8 ± 0.5 2.7 ± 0.5
Minimum Lumen Diameter (mm) 0.9 ± 0.5 1.0 ± 0.5
Diameter stenosis (%) 66.7 ± 14.3 65.3 ± 14.5Postprocedure Minimum Lumen Diameter (mm) In-stent 2.6 ± 0.5 2.6 ± 0.4 In-segment 2.3 ± 0.5 2.3 ± 0.5 Diameter stenosis (%) In-stent 6.9 ± 7.2 7.1 ± 7.7 In-segment 17.4 ± 7.0 17.4 ± 6.6 Device Success (%) 100 100Procedure Success (%) 97.7 97.4
Baseline Procedural Characteristics
No statistical significance between study arms
Procedural Characteristics: All Lesions
Source: Ruiz-Salmeron R. Poster presentation. TCT, Washington DC, USA, September 2014.
Baseline & Lesion CharacteristicsLesion Location
Lesion Type
Orsiro (N=332)
Xience Prime (N=173)Orsiro
(N = 298)Xience Prime
(N = 154)
Age, years mean ± SD 62.7 ± 10.4¹ 64.8 ± 9.2¹
Gender male (%) 78.2 74.7
Hypertension (%) 77.5 77.3
Hyperlipidemia (%) 67.8 73.4
History of MI (%) 30.2² 20.1²
Renal Insufficiency (%) 7.0 4.5
Congestive Heart Failure (%) 10.1 13.6
Diabetes (%) 28.2 28.6
Insulin dependent (%) 21.4 34.1
Non-insulin dependent (%) 78.6 65.9
Smoking (%) 66.4 57.8
History of stroke TIA (%) 7.0 6.5
Patient Characteristics
Source: Ruiz-Salmeron R. Poster presentation. TCT, Washington DC, USA, September 2014.
¹p=0.0344, ²p=0.0219.
Angiographic Results at 9 Months
OrsiroN = 278
Xience PrimeN = 149
Late loss (mm) In-stent 0.10± 0.32 0.11 ± 0.29 In-segment 0.09 ± 0.35 0.09 ± 0.33
MLD (mm) In stent 2.52 ± 0.56 2.48 ± 0.50 In segment 2.25 ± 0.55 2.22 ± 0.56
Diameter stenosis (%) In stent 9.52 ± 13.49 9.43 ± 10.78 In segment 19.48 ± 12.89 19.22 ± 12.25
Binary restenosis (%) In stent 6 (2.16%) 2 (1.34%) In segment 11 (3.96%) 7 (4.70%)
Source: Windecker S. Oral presentation. EuroPCR, Paris, France. 21 May 2013.
Primary Enpoint: In-Stent LLL at 9 Months
P non-inferiority = <0.0001Difference = 0.0095% CI = -0.06 to 0.06
OrsiroXience Prime
Major Secondary Endpoints: Angiographic Results at 9 Months
0.11 ± 0.29 mm
0
-1.0In-Stent LLL (mm)
Cum
ulati
ve F
requ
ency
(%) 0.10 ± 0.32 mm
20
40
60
80
100
-0.5 0.0 0.5 1.0 1.5 2.0
No statistical significance between study arms
Xience Prime™ (N=154)Orsiro (N=298)
0.0
10
20
0 180 365 730
TLF
univ
. def
. (%
)
8.4%10.0%
P = 0.5648
Days after PCI
Clinical Results at 24 Months All Subjects
TLF at 24 months – All Subjects
Source: Ruiz-Salmeron R. Poster presentation. TCT, Washington DC, USA, September 2014.
Clinical Results at 24 Months Diabetic Subgroup
TLF at 24 months – Diabetic Subgroup
Source: Ruiz-Salmeron R. Poster presentation. TCT, Washington DC, USA, September 2014.
0%
10%
20%
0 180 365 730
9.7%9.1%
P = 0.8975
Days after PCI
TLF
univ
. def
. (%
)
Xience Prime™ (N=44)Orsiro (N=84)
Clinical Results at 24 Months Small Vessel Subgroup
TLF at 24 months – Small Vessel Subgroup
Source: Ruiz-Salmeron R. Poster presentation. TCT, Washington DC, USA, September 2014.
TLF
univ
. def
. (%
)
Xience Prime™ (N=91)Orsiro (N=168)
9.4%13.3%
P = 0.3153
0%
10%
20%
0 180 365 730Days after PCI
Sten
t thr
ombo
sis
(%)
0.0
10
0 180 365 7300.0%
Days after PCI
0.7%P = 0.3407
Stent Thrombosis at 24 Months All Subjects
Stent Thrombosis at 24 months – All Subjects
Source: Ruiz-Salmeron R. Poster presentation. TCT, Washington DC, USA, September 2014.
Xience Prime™ (N=154)Orsiro (N=298)
0.0%0.0%
Days after PCI
0.0
10
0 180 365 730
P = >0.9999
0.0
10
0 180 365 730
P = 0.3437
Days after PCI
ST (%
)
0.0%2.3%
Stent Thrombosis at 24 Months Subgroups
Stent Thrombosis at 24 months – Diabetic Subgroup
Source: Ruiz-Salmeron R. Poster presentation. TCT, Washington DC, USA, September 2014.
Xience Prime™ (N=91)Orsiro (N=168)
Stent Thrombosis at 24 months – Small Vessel Subgroup
ST (%
)
Xience Prime™ (N=44)Orsiro (N=84)
Stent Thrombosis at 24 Months
Orsiro
N = 298
Xience Prime
N = 154
Acute (0-48h) 0 % 0 %
Subacute (48h-30d) 0 % 0 %
Late (>30d-12m) 0 % 0 %
Very late (>12m) 0% 0%
Overall 0 % 0 %
Orsiro
N = 298
Xience Prime
N = 154
Acute (0-48h) 0 % 0 %
Subacute (48h-30d) 0 % 0 %
Late (>30d-12m) 0 % 0 %
Very late (>12m) 0% 0.7%
Overall 0 % 0.7 %
Definite Stent Thrombosis Definite, Probable and Possible Stent Thrombosis
Source: Ruiz-Salmeron R. Poster presentation. TCT, Washington DC, USA, September 2014.
OCT and IVUS results at 9 Months
Source: Byrne R., EuroPCR, Paris, France, May 2014. Oral Presentation.Source: Windecker S. TCT, San Francisco, USA, October 2013. Oral presentation.
Maturity: 58.8% [13.5 – 92.9]
Maturity: 64.2% [8.9 – 97.0]
Adjusted p value = 0.62
Orsiro Xience Prime P
Well-apposed struts 98.6% 98.8% 0.62
Incomplete Strut Apposition 1.0% 0.6% 0.32
Non-apposed side branch 0.4% 0.6% 0.37
Covered Struts 98.3% 97.5% 0.042
Neointimal Area
1.00 ± 0.44 mm2
0.74 ± 0.38 mm2
P=0.024
Apposition and coverage
IVUS results at 9 Months
Source: Byrne R., EuroPCR, Paris, France, May 2014. Oral Presentation.Source: Windecker S. TCT, San Francisco, USA, October 2013. Oral presentation.
Mature
Immature
-0.4
-0.3
-0.2
-0.1
0
0.1
0.2
0.3
0.4
0.5
-0.10
0.16
-0.34
0.43
9-month IVUS Results
Orsiro (N=31)
Xience Prime (N=25)
Δ Mean lumen area @ 9 M FUP
Δ Neointimal hyperplasia @ 9 M FUP
P = 0.34 P = 0.043
Stent apposition by IVUS @ 9-month FUP was 100% in both study arms
OCT appearance at 9 MonthsOrsiro
Neointima coverage
Xience Prime
Neointima coverage
*With the courtesy of Prof. Haude/Neuss
Source: Lefèvre T., Oral presentation, TCT 2013, San Francisco, USA.
Conclusion Orsiro is a thin-strut cobalt-chromium sirolimus-eluting stent with a biodegradable
polymer coating. In this randomized controlled trial the clinical event rates of the Orsiro SES with a
biodegradable polymer were low and comparable to the Xience Prime up to 24 months in all three analyzed populations.
One possible late stent thrombosis occurred in the Xience Prime™ diabetic cohort. No stent thrombosis was observed in the Orsiro cohorts through 24 months.
The BIOFLOW-II OCT/IVUS sub group analysis showed similar results between the Orsiro and Xience Prime.
Safe inhibition of neointimal hyperplasia was seen in both arms with struts well covered with a thin, uniform neointima.
Orsiro was associated with a significantly lower area of neointimal hyperplasia than Xience Prime.
Orsiro achieved an excellent strut apposition.